A Comprehensive Guide to Medicare Coverage For GLP-1 Injections

Whether Medicare covers a GLP-1 injection like Wegovy, Zepbound, Ozempic, or Mounjaro depends mostly on why it's prescribed. Medicare drug plans (Part D) have long covered GLP-1s for type 2 diabetes and certain other conditions. And since July 1, 2026, a new Medicare program called the GLP-1 Bridge lets eligible people with Medicare drug coverage get Wegovy or Zepbound for weight loss for a $50 monthly copay. Here's which brands to know, the different ways to get coverage, what you'll pay, and how to choose.

The GLP-1 Injections to Know

GLP-1 medicines mimic a natural hormone that helps control blood sugar and appetite. Most are once-weekly injections given with a prefilled pen. They share two main active ingredients, sold under different brand names for different uses:

Ozempic (semaglutide): approved for type 2 diabetes, with added heart and kidney benefits for some people with diabetes.
Wegovy (semaglutide): approved for chronic weight management, to lower the risk of heart attack and stroke in people with heart disease and excess weight, and for a type of fatty liver disease (MASH).
Mounjaro (tirzepatide): approved for type 2 diabetes.
Zepbound (tirzepatide): approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.
Trulicity (dulaglutide): a weekly injection for type 2 diabetes.
Victoza and Saxenda (liraglutide): older daily injections for diabetes (Victoza) and weight management (Saxenda), now also available as lower-cost generic liraglutide.

Oral options also exist, including the Wegovy pill and Lilly's Foundayo pill for weight loss and Rybelsus for diabetes. This guide focuses on the injections.

How Medicare Covers GLP-1 Injections: The Main Pathways

1. Your Part D plan, for diabetes and other approved medical uses

Medicare drug plans can cover GLP-1s prescribed for a medically accepted use other than weight loss alone. That includes Ozempic, Mounjaro, Trulicity, and liraglutide for type 2 diabetes; Wegovy to reduce heart risk in people with heart disease; Zepbound for obstructive sleep apnea; and Wegovy for MASH liver disease. Coverage depends on your plan's formulary, and most plans require prior authorization showing the drug is being used for the covered condition.

2. The Medicare GLP-1 Bridge, for weight loss

By law, Medicare drug plans have generally been barred from covering drugs used only for weight loss. The Medicare GLP-1 Bridge is a temporary federal program that fills that gap outside your regular plan benefit.

When it runs: July 1, 2026, through December 31, 2027. It was extended after a separate longer-term program for Part D plans, called BALANCE, was delayed.
Which injections it covers: Wegovy and Zepbound in the KwikPen form. It also covers the Wegovy and Foundayo pills.
What you pay: a flat $50 copay for each 28- or 30-day fill.
Who qualifies: adults 18 or older with Medicare drug coverage (a stand-alone Part D plan or a Medicare Advantage plan with drug coverage) who meet one of these at the time they start the medicine:
- a BMI of 35 or higher;
- a BMI of 30 or higher plus heart failure with preserved ejection fraction, uncontrolled high blood pressure despite two blood pressure medicines, or chronic kidney disease stage 3a or higher; or
- a BMI of 27 or higher plus prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease.
Who uses a different route: people with type 2 diabetes, obstructive sleep apnea, or MASH get their GLP-1 through their regular Part D plan instead.
How approval works: your prescriber submits a prior authorization request to a central Medicare processor, not to your drug plan. Your prescriber doesn't need to be enrolled in Medicare.

For a closer look at one drug, see our guide to Medicare coverage for Zepbound.

3. Medicaid, if you qualify for both programs

If you have both Medicare and Medicaid, your Medicare drug plan is still your main drug coverage, and people with both who meet the Bridge criteria can use it. Medicaid coverage of weight-loss drugs varies by state, so check with your state Medicaid office.

4. What Medicare doesn't cover

Part B doesn't cover GLP-1 injections you give yourself at home; they fall under drug coverage.
Compounded or "generic-style" semaglutide or tirzepatide from online sellers isn't covered and isn't FDA-approved.
Manufacturer savings cards can't be used by people with Medicare.

How to Get Medicare Coverage for a GLP-1, Step by Step

Confirm you have Medicare drug coverage. You need a Part D plan or a Medicare Advantage plan with drug coverage. Unsure of your status? See Medicare eligibility requirements and how to check your status.
Talk with your doctor about why you'd take it. The reason (diabetes, heart risk, sleep apnea, liver disease, or weight loss) decides which coverage path applies. If you need a new doctor, see how to find a doctor who accepts Medicare.
Bring your records. Your doctor will need your BMI and any qualifying diagnoses documented at the time you start the medicine.
Your prescriber requests approval. For Part D uses, that goes to your plan; for weight loss under the Bridge, it goes to Medicare's central processor.
Fill at the pharmacy. Once approved, you pay your plan's cost-sharing, or $50 under the Bridge.
If you're denied, ask why. Plan denials can be appealed; Bridge criteria are fixed by Medicare, so a denial there usually means a criterion wasn't documented or met.

What GLP-1 Injections Cost With Medicare

Under the GLP-1 Bridge: $50 per monthly fill. That $50 doesn't count toward your Part D deductible or toward the yearly out-of-pocket cap.
Under your Part D plan: your copay or coinsurance depends on the drug's tier, your plan's deductible, and where you are in the year. In 2026, Part D out-of-pocket drug costs are capped at $2,100 a year; the cap is adjusted annually.
Price changes ahead: starting in 2027, a lower Medicare-negotiated price takes effect for semaglutide (Ozempic, Wegovy, and Rybelsus). That changes what Medicare pays; your own copay will still depend on your plan.
If you pay cash instead: as of mid-2026, manufacturer self-pay programs listed Wegovy at about $349 a month for standard doses through NovoCare Pharmacy, and Zepbound vials at $299 to $449 a month depending on dose through LillyDirect. Prices change often, so check current rates.

Programs That Can Help With Costs

Extra Help: Medicare's Low-Income Subsidy lowers Part D premiums, deductibles, and copays for people with limited income and savings.
Medicare Savings Programs and Medicaid: state programs that can help with premiums and cost-sharing.
Medicare Prescription Payment Plan: lets you spread your Part D drug costs into monthly payments instead of paying large amounts at the pharmacy.
State pharmaceutical assistance programs: some states help residents with Medicare pay for prescriptions.
Manufacturer patient assistance programs: each has its own income and insurance rules, and some exclude people with Medicare drug coverage, so check eligibility first. See our guides to Wegovy patient assistance programs and Zepbound patient assistance programs.
TrumpRx: a federal website, launched in February 2026, that points cash-paying patients to manufacturers' direct prices.

How to Choose the Right GLP-1 for You

The right medicine is a decision for you and your doctor, but these questions help narrow it down:

What is it for? If you have type 2 diabetes, Ozempic, Mounjaro, or Trulicity through Part D is usually the path. For weight loss, Wegovy or Zepbound through the Bridge. For sleep apnea, Zepbound; for heart risk reduction or MASH, Wegovy.
Which is on your plan's formulary? Plans often prefer one brand. Check the formulary and tier before you start.
How do they differ? Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are both weekly injections. Tirzepatide acts on two hormone pathways and has generally produced somewhat more weight loss in studies, but results, side effects, and tolerance vary by person.
What about side effects? Nausea, vomiting, diarrhea, and constipation are common, especially when starting or increasing a dose. Ask your doctor about risks given your health history.
Which form is covered? For weight loss under the Bridge, Zepbound is covered only as the KwikPen, not the self-pay vials.

Plan Ahead: Open Enrollment and 2027

Medicare Open Enrollment runs from October 15 to December 7. If you take or plan to take a GLP-1, compare 2027 plan formularies now, and keep in mind that you'll need Medicare drug coverage in 2027 to keep using the Bridge. If you're also weighing Medicare Advantage or a Medigap policy, see Medicare Advantage rule changes in 2027 and choosing a Medicare Supplement plan.

Protect Yourself

Be wary of ads promising "free Ozempic" or "Medicare-approved" compounded shots.
Never give your Medicare number to an unsolicited caller or website.
Fill prescriptions only at licensed pharmacies.

The Bottom Line

Medicare now offers more than one route to GLP-1 injections. For diabetes, heart risk, sleep apnea, or MASH, coverage runs through your Part D plan. For weight loss, the Medicare GLP-1 Bridge covers Wegovy and the Zepbound KwikPen for $50 a month through 2027 if you meet the criteria. Start with your doctor, check your plan's formulary, and look into Extra Help and other programs if costs are a concern.

This article is general information, not medical advice, and isn't affiliated with Medicare or any drug manufacturer. Rules and prices change; confirm details with your doctor, your plan, or 1-800-MEDICARE.